Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

January 16, 2007; 68 (3) Articles

Outcome of noninvasive ventilation in children with neuromuscular disease

H. K. Young, A. Lowe, D. A. Fitzgerald, C. Seton, K. A. Waters, E. Kenny, L. S. Hynan, S. T. Iannaccone, K. N. North, M. M. Ryan
First published January 15, 2007, DOI: https://doi.org/10.1212/01.wnl.0000251299.54608.13
H. K. Young
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Lowe
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. A. Fitzgerald
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Seton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K. A. Waters
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E. Kenny
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L. S. Hynan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. T. Iannaccone
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K. N. North
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. M. Ryan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Outcome of noninvasive ventilation in children with neuromuscular disease
H. K. Young, A. Lowe, D. A. Fitzgerald, C. Seton, K. A. Waters, E. Kenny, L. S. Hynan, S. T. Iannaccone, K. N. North, M. M. Ryan
Neurology Jan 2007, 68 (3) 198-201; DOI: 10.1212/01.wnl.0000251299.54608.13

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
437

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Objective: To assess the effect of institution of noninvasive ventilation (NIV) on clinical outcome and quality of life (QOL) in a cohort of children with severe neuromuscular disorders.

Methods: We reviewed records and obtained clinical data from the year prior to commencing NIV and annually thereafter. Data obtained included diagnosis, patient symptoms, mortality, NIV adverse effects, pulmonary function tests, polysomnographic data, length of hospitalizations, and health care costs. Patients and parents completed questionnaires assessing QOL with NIV and recalling QOL before NIV.

Results: Fourteen of 17 (82%) suitable patients were enrolled. Follow-up ranged from 6 to 84 months (median 30). Symptoms of daytime sleepiness (p = 0.003) and headache (p = 0.046) improved after initiation of NIV. Sleep quality assessed by polysomnography also improved. Hospitalization rates (p = 0.002) and health care costs (p = 0.003) decreased. QOL remained stable after NIV, despite disease progression.

Conclusion: Treatment of respiratory failure, in children with neuromuscular disease, with noninvasive ventilation results in a reduction in symptoms, hospitalizations, and health care costs without adverse effects on quality of life.

Noninvasive ventilation (NIV) is an effective symptomatic treatment for adults with neuromuscular respiratory failure.1 The optimal timing of initiation of NIV and its impact on quality of life (QOL) in children are unknown.2–4 In this study, we sought to establish the effect of institution of NIV on clinical outcome and QOL in a cohort of children with severe neuromuscular disorders.

Methods.

NIV was defined as the delivery of ventilatory support via a nasal or face mask interface without the need for an invasive artificial airway.

Inclusion criteria included all patients commencing nocturnal NIV for respiratory compromise associated with neuromuscular disorders at The Children's Hospital at Westmead during the period January 1, 1994, to January 1, 2004. Toddlers and children who had severe cognitive deficits rendering them unable to communicate were excluded from the QOL analysis, but included in the remainder of the study. Records were reviewed and data obtained from the year prior to institution of NIV and annually thereafter. The study had institutional ethics committee approval.

Data obtained included diagnosis, age at institution of NIV, nature of NIV, mortality, patient symptoms, growth centiles, presence of scoliosis, results of pulmonary function testing, overnight oximetry or polysomnography (PSG), number of hospitalizations, number of days in hospital and intensive care, and costs to the health service. Pulmonary function testing was performed annually in all children able to cooperate, in a seated or erect position, using a Sensormedics Vmax Spirometer.

Sleep-disordered breathing (SDB) was assessed using questionnaires and overnight study data. Details of symptoms were obtained from clinical records and questionnaires completed prior to PSG and before and after initiation of NIV. PSG data were obtained using the Compumedics S-series polysomnographic system. Data collected included frequency and duration of apneas and hypopneas, maximum transcutaneous CO2 (TCO2), minimum O2 saturation, average O2 desaturation, respiratory disturbance index (RDI), and RDI in REM sleep.5 The RDI was defined as the number of abnormal respiratory events (apneas and hypopneas) per hour of sleep. PSG was performed in the year prior to NIV and annually thereafter.

Direct costs associated with outpatient visits and hospital admissions prior to institution of NIV were calculated. These were obtained from the finance departments of the tertiary hospital, the patients' local hospitals, and the ambulance service. Additional costs after NIV included equipment and specialized nursing costs. Total costs were underestimated as visits to general practitioners, medications obtained externally, and indirect costs (such as loss of parental income) were not included.

The QOL study described in this paper was carried out using the Pediatric Quality of Life Inventory (PedsQL), developed by Dr. James W. Varni. Parents and children evaluated QOL in several different areas using both the PedsQL version 4.0 (PedsQL 4.0) generic and neuromuscular modules.6,7 Different versions of the PedsQL were used in the following age groups; toddler, 0 to 2 years; young child, 3 to 7 years; child, 8 to 11 years; and teenager, 12 to 18 years. Scores were converted to a 0 to 100% scale, with higher scores indicating higher QOL. In order to establish the effect of NIV on QOL, parents completed two sets of questionnaires: one recalling what life had been like for their child prior to commencing NIV and one addressing their QOL after institution of NIV.

Statistical analysis was performed using SPSS for Windows version 11. The Wilcoxon nonparametric related samples test was used to compare means of categorical data including patients' symptoms, QOL, and health care costs before and after NIV. Repeated-measures analysis of variance assessed changes in PSG data over time. Differences in PSG data in patients with and without symptoms were compared using the Mann-Whitney U test for nonparametric unrelated samples. Intraclass correlation was used to measure correlation between child- and parent-reported QOL.

Results.

Seventeen patients were eligible for inclusion. Fourteen children (82%) were enrolled. Diagnoses included spinal muscular atrophy type 2 (six children), Duchenne muscular dystrophy (three children), congenital myopathy (one child), merosin-deficient muscular dystrophy (one child), Arts syndrome (one child), and myotonic dystrophy (one child). Three refused or had been transferred to adult units. Nine subjects were girls. Three patients commenced NIV between 1994 and 1999. Eleven patients commenced NIV between 2000 and 2004. The median age of patients at initiation of NIV was 7.7 years (range 1.5 to 16 years) and reflected the underlying disease (see table E-1 on the Neurology Web site at www.neurology.org). The median length of follow-up was 30 months (range 6 to 84 months).

Initial assessment and treatment.

In six children (43%), NIV was instituted during an elective hospital admission. In five cases, this was based on a full PSG (RDI >10, maximum TcCO2 >15 mm Hg baseline in sleep, or recurrent desaturations <90%), and in one case, this was based on adverse overnight oximetry (Sao2) and transcutaneous CO2 with follow-up PSG undertaken after 6 months.

Eight patients first received NIV during an acute illness associated with a respiratory tract infection. Two of these patients had not undergone PSG in the preceding year. Six had undergone prior PSG, which in two cases had indicated the need for ventilatory support, but their acute admission occurred before NIV could be instituted electively. In the other four cases, prior PSG had not suggested a need for ventilatory support. Three of these patients had been admitted to the intensive care unit at least once. The fourth had been admitted to hospital with respiratory illnesses eight times in the preceding year (see table E-1 on the Neurology Web site at www.neurology.org).

Thirteen patients commenced ventilatory support with bilevel positive airway pressure support devices (BIPAP Harmony, Respironics, Inc., Murrysville, PA, or Resmed VPAP 11 ST, Sydney, NSW, Australia). One child commenced nocturnal continuous positive airway pressure (Solo Plus Lx, Respironics, Inc.).

All the children received regular physiotherapy during hospital admissions. In-exsufflator devices were not used. None of the boys with Duchenne muscular dystrophy were receiving treatment with steroids at initiation of NIV.

Symptoms and QOL scores.

Nine patients had daytime somnolence prior to NIV. Four also had morning headaches. Following NIV, no children had daytime sleepiness (p = 0.003) and only one continued to have headaches (p = 0.046) (figure). Although several PSG indices also improved, no association was found between the abnormalities in PSG data and symptoms of SDB. Before NIV, seven patients had anorexia and four had failure to thrive (weight below the third centile for age). After NIV, only three patients had anorexia, but five had failure to thrive.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure. Patients' symptoms before and after noninvasive ventilation (NIV).

Five patients experienced adverse effects related to NIV. Two children reported finding the mask initially uncomfortable but required no change in treatment. Three children developed skin breakdown over the nasal bridge, necessitating dressings or change to a full-face mask. One child experienced nausea, and one developed midface hypoplasia after 4 years of NIV.

One patient, a 16-year-old boy with Duchenne muscular dystrophy, developed acute respiratory failure during a respiratory infection and died despite full resuscitative efforts. PSG and echocardiography performed while on NIV 6 months prior to his death were within normal limits.

Eleven (79%) parents completed parent report forms from both QOL questionnaires before and after NIV. There was no significant deterioration in parent-reported QOL in any of the subscales after NIV (table E-2). Three children (ages 8 to 12) and four teenagers (ages 13 to 18) completed child report forms after NIV only. The PedsQL 4.0 generic total QOL for children ranged from 32% to 77.9%, and the generic total QOL for teenagers ranged from 32.1% to 79.1% Actual PedsQL 4.0 QOL child report scores are shown in table E-3. Published PedsQL QOL values for children with other chronic illness and children with spinal muscular atrophy (SMA) are given in tables E-2 and E-3 for comparison. Intraclass correlation between the child and adult reported QOL was 0.94, p = 0.002. The lowest PedsQL 4.0 QOL scores were consistently in the physical health domains for both parent- and child-reported QOL

Hospitalization and health care costs.

Patients were hospitalized for a mean of 41.7 days/y (range 0 to 82) in the year preceding NIV. In the year after NIV, this decreased by 73% to a mean of 10.5 days/y (range 0 to 52) (p = 0.002). The mean annual number of hospitalizations in the year before NIV was 3.8/y. This decreased to 0.7/y after NIV (p = 0.002). The mean time spent in the pediatric intensive care unit (PICU) decreased from 10.2 days (before NIV) to 2.3 days after NIV (p = 0.06).

Mean annual days in hospital also decreased after NIV in those children ventilated emergently who had normal PSG prior to NIV (p = 0.012). The mean annual direct cost of health care per patient decreased from $55,129.00 in the year prior to institution of ventilation to $14,914.00 in the year following NIV (p = 0.003).

Respiratory assessments, including PSG.

Seven patients underwent pulmonary function testing (PFT) prior to commencing NIV at a median age of 13 years (range 7 to 16) (table). In three of these patients, repeat PFT showed no change in pulmonary function after NIV. The remaining patients were unable to perform repeat PFT.

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table Mean pulmonary function test results before and 1 year after NIV

In two patients, formal PSG data were not available prior to commencing NIV. One had undergone overnight oxygen saturation monitoring and transcutaneous capnometry. The PSG data from the other patient was lost. One patient had not undergone PSG after commencing NIV at the time of this review. Six patients had serial PSG studies available from the year preceding NIV and for 2 years after NIV (table E-4). After NIV, the rate of apneas and hypopneas decreased (p = 0.035) and the RDI (p = 0.013) and the RDI in REM sleep (p = 0.009) improved. Although there were trends toward improvement in baseline oxygen saturation and peak CO2 levels, these differences were not significant.

Discussion.

Institution of NIV in children with neuromuscular disease resulted in a reduction in hospital and intensive care unit admissions and a 73% reduction in health care costs over the year after treatment, without adversely affecting the QOL of the patient or family. Improvements were also observed in patients' symptoms and PSG indices.

The reduction in hospital admissions was seen in all subgroups, including those children with normal PSG data prior to emergent ventilation. Hospitalizations may have been further decreased by earlier institution of NIV. This has not been well studied in children with neuromuscular disorders, the only previous such study having been skewed by inclusion of a number of children with cardiac disease.8,9

Health service costs also decreased markedly after NIV. Cost reduction may be offset by prolonged survival, but this study was not designed to demonstrate survival advantage. Health professionals have become accountable for resource allocation, particularly in patients with progressive incurable disease. It could be postulated that indirect costs (i.e., parental loss of earnings) would also decrease after NIV. QOL scores that addressed family resources did not improve after NIV, however, suggesting that earning capacity remains curtailed in these families despite a reduction in their children's hospitalizations.

As the children in this study had progressive neuromuscular disorders, it could be expected that their QOL would deteriorate with increasing age. We found, however, that QOL remained stable after NIV despite disease progression, suggesting that NIV may prevent deterioration in QOL. These results must be interpreted with caution as the QOL data prior to NIV may have been affected by recall bias. Not surprisingly, lowest QOL scores were in physical health domains, but, despite their severe physical limitations, most children considered their emotional and social well-being to be good. The considerable pressures involved in caring for a ventilator-dependent child should not be underestimated.10 Despite this, parents reported limitation of family activities with no deterioration after NIV, suggesting that NIV was not additionally detrimental to the QOL of the family unit.

Patients' symptoms of headache and daytime somnolence improved significantly after NIV. Although several PSG indices also improved, no association was found between the abnormalities in PSG data and symptoms of SDB. This disparity has been identified by other authors and remains poorly understood.11

Although NIV should reduce the work of breathing and metabolic demands, rates of failure to thrive remained high after NIV, possibly because of factors such as bulbar dysfunction. Malnutrition can cause reduced ventilatory drive, impaired immune function, and respiratory muscle wasting. Nutritional monitoring is therefore important in children with chronic neuromuscular respiratory failure.12

NIV should ideally be offered electively in order to avoid difficult decision making in an emergency situation. The frequency of emergent initiation of NIV in this and other studies suggests that current means of assessment or monitoring of respiratory function are inadequate.13 Children may be too young or too intellectually disabled to report symptoms of SDB or to cooperate with PFT or may present with severe hypoventilation in the absence of previous symptoms of SDB. Future research in this patient group should address use of pulmonary function assessment techniques that do not require patient cooperation (such as forced oscillation and nitrogen washout techniques).14

PSG is considered the gold standard for the diagnosis of SDB in children,15 but does not adequately identify children whose respiratory function worsens acutely with respiratory infections. This potential for acute decompensation is suggested by a history of frequent hospitalizations or PICU admissions. Such findings should be considered when assessing children for NIV, particularly those unable to perform PFT or report symptoms of SDB. Performing PSG (or at least overnight oximetry and transcutaneous capnography) at the time of admission for respiratory tract infections may identify children in whom infection precipitates respiratory insufficiency.16 Future research in this patient group should focus on reliable diagnosis of respiratory insufficiency and the optimal timing of institution of NIV.

Footnotes

  • Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the January 16 issue to find the link for this article.

    Disclosure: The authors report no conflicts of interest.

    Received May 5, 2006. Accepted in final form October 9, 2006.

References

  1. 1.↵
    Annane D, Chevrolet JC, Chevret S, et al. Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders. Cochrane Database Syst Rev 2000;2:CD001941.
  2. 2.↵
    Simonds AK, Ward S, Heather S, et al. Outcome of paediatric domiciliary mask ventilation in neuromuscular and skeletal disease. Eur Respir J 2000;16:476–481.
    OpenUrlAbstract/FREE Full Text
  3. 3.
    Katz S, Selvadurai H, Keilty K, et al. Outcome of non-invasive positive pressure ventilation in paediatric neuromuscular disease. Arch Dis Child 2004;89:121–124.
    OpenUrlAbstract/FREE Full Text
  4. 4.
    Wallgren-Pettersson C, Bushby K, Mellies U, et al. ENMC. 117th ENMC workshop: ventilatory support in congenital neuromuscular disorders—congenital myopathies, congenital muscular dystrophies, congenital myotonic dystrophy and SMA (II) 4–6 April 2003, Naarden, The Netherlands. Neuromuscul Disord 2004;14:56–69.
    OpenUrlCrossRefPubMed
  5. 5.↵
    Rechtschaffen A, Kales AD. A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. US Department of Health, Education, and Welfare Public Health Service 1968.
  6. 6.↵
    Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care 2001;39:800–812.
    OpenUrlCrossRefPubMed
  7. 7.
    Iannaccone ST, Hynan LS. American Spinal Muscular Atrophy Randomized Trials (AmSMART) Group. Reliability of 4 outcome measures in pediatric spinal muscular atrophy. Arch Neurol 2003;60:1130–1136.
    OpenUrlCrossRefPubMed
  8. 8.↵
    Raphael JC, Chevret S, Chastang C, et al. Randomised trial of preventive nasal ventilation in Duchenne muscular dystrophy. French Multicentre Cooperative Group on Home Mechanical Ventilation Assistance in Duchenne de Boulogne Muscular Dystrophy. Lancet 1994;343:1600–1604.
    OpenUrlCrossRefPubMed
  9. 9.
    Norregaard O. Noninvasive ventilation in children. Eur Respir J 1920;5:1332–1342.
    OpenUrl
  10. 10.↵
    Miller JR, Colbert AP, Schock NC. Ventilator use in progressive neuromuscular disease: impact on patients and their families. Dev Med Child Neurol 1988;30:200–207.
    OpenUrlPubMed
  11. 11.↵
    Mellies U, Ragette R, Schwake C, et al. Daytime predictors of sleep disordered breathing in children and adolescents with neuromuscular disorders. Neuromuscul Disord 2003;13:123–8.
    OpenUrlCrossRefPubMed
  12. 12.↵
    Aldrich TK. Nutritional factors in the pathogenesis and therapy of respiratory insufficiency in neuromuscular diseases. Monaldi Arch Chest Dis 1993;48:327–330.
    OpenUrlPubMed
  13. 13.↵
    Sritippayawan S, Kun SS, Keens TG, et al. Initiation of home mechanical ventilation in children with neuromuscular diseases. J Pediatr 2003;142:481–485.
    OpenUrlCrossRefPubMed
  14. 14.↵
    Oostveen E, MacLeod D, Lorino H, et al. The forced oscillation technique in clinical practice: methodology, recommendations and future developments. Eur Respir J 2003;22:1026–1041.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    American Thoracic Society. Standards and indications for cardiopulmonary sleep studies in children. Am J Respir Crit Care Med 1996;153:866–878.
    OpenUrlCrossRefPubMed
  16. 16.↵
    Mier-Jedrzejowicz A, Brophy C, Green M. Respiratory muscle weakness during upper respiratory tract infections. Am Rev Respir Dis 1988;138:5–7.
    OpenUrlPubMed

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Methods.
    • Results.
    • Discussion.
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Topics Discussed

  • All Pediatric
  • All Medical/Systemic disease
  • Anterior nerve cell disease
  • Muscle disease

Alert Me

  • Alert me when eletters are published
Neurology: 98 (19)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise